학술논문

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22
Document Type
Article
Source
In: Clinical Cancer Research. (Clinical Cancer Research, May 2021, 27(10):2742-2754)
Subject
Language
English
ISSN
15573265
10780432